1-20 of 39
Kenneth Cusi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

1352-P: Cardiometabolic Risk Factors Superior to FIB4 in Identifying Adults at Risk for NAFLD with Fibrosis

EDDISON GODINEZ LEIVA, ANU SHARMA, SRILAXMI KALAVALAPALLI, ANDREA ORTIZ ROCHA, ENRIQUE VALDEZ SAENZ, YASMINE MOHSENI, NATHALY CUERVO PARDO, JENS T. ROSENBERG, JOSEPH R. GRAJO, DIANA BARB, KENNETH CUSI
Journal: Diabetes
Diabetes 2024;73(Supplement_1):1352-P
https://doi.org/10.2337/db24-1352-P
Published: 14 June 2024
View articletitled, 1352-P: Cardiometabolic Risk Factors Superior to FIB4 in Identifying Adults at Risk for NAFLD with Fibrosis
Meeting Abstracts

1414-P: Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Experience Significant Disease Burden and Stigma

ZOBAIR YOUNOSSI, YUSUF YILMAZ, JIAN-GAO FAN, MING-HUA ZHENG, KHALID AIDA ALSWAT, SALEH ALQAHTANI, MOHAMED EL-KASSAS, LAURENT CASTERA, JESUS FUNUYET-SALAS, MANUEL ROMERO-GOMEZ, VINCENT W. WONG, SHIRA ZELBER-SAGI, SOMBAT TREEPRASERTSUK, ALINA ALLEN, HIROKAZU TAKAHASHI, TAKUMI KAWAGUCHI, SVEN FRANCQUE, AJAY DUSEJA, JOERN M. SCHATTENBERG, PATRIZIA BURRA, PATRIZIA CARRIERI, MARCO ARRESE, YUICHIRO EGUCHI, ASHWANI SINGAL, STUART GORDON, LINDA HENRY, KENNETH CUSI, PEGAH GOLABI, MARIA STEPANOVA, JEFFREY V. LAZARUS
Journal: Diabetes
Diabetes 2024;73(Supplement_1):1414-P
https://doi.org/10.2337/db24-1414-P
Published: 14 June 2024
View articletitled, 1414-P: Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Experience Significant Disease Burden and Stigma
Meeting Abstracts

1349-P: Diabetes in Chronic Pancreatitis Is Characterized by Significant Insulin Deficiency

YOGISH C. KUDVA, YISHENG LI, FUCHENCHU WANG, DHIRAJ YADAV, DANA K. ANDERSEN, ZEB I. SAEED, MELENA BELLIN, WILLIAM E. FISHER, KENNETH CUSI, WALTER PARK, SHAFAQ RAZA RIZVI, FREDERICO G. TOLEDO, ROBERT V. CONSIDINE, JOSE SERRANO, MARK O. GOODARZI, PHIL HART
Journal: Diabetes
Diabetes 2024;73(Supplement_1):1349-P
https://doi.org/10.2337/db24-1349-P
Published: 14 June 2024
View articletitled, 1349-P: Diabetes in Chronic Pancreatitis Is Characterized by Significant Insulin Deficiency
Meeting Abstracts

1367-P: Type 2 Diabetes Mellitus and Obesity Amplifies Nonalcoholic Fatty Liver Disease Risk with Age

ANU SHARMA, EDDISON GODINEZ LEIVA, ROMINA LOMONACO, ENRIQUE VALDEZ SAENZ, ANDREA ORTIZ ROCHA, MARIA A. GONZALEZ, STEPHEN A. MARANGI, SULAV SHRESTHA, SHWETHA S. SHETTY, JEFFREY T. BUDD, SRILAXMI KALAVALAPALLI, DIANA BARB, KENNETH CUSI
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1367-P
https://doi.org/10.2337/db23-1367-P
Published: 20 June 2023
View articletitled, 1367-P: Type 2 Diabetes Mellitus and Obesity Amplifies Nonalcoholic Fatty Liver Disease Risk with Age
Meeting Abstracts

1366-P: Nonalcoholic Fatty Liver Disease in Young-Onset Type 2 Diabetes Mellitus—A New Epidemic?

ANU SHARMA, EDDISON GODINEZ LEIVA, ROMINA LOMONACO, ENRIQUE VALDEZ SAENZ, ANDREA ORTIZ ROCHA, STEPHEN A. MARANGI, MARIA A. GONZALEZ, SULAV SHRESTHA, SHWETHA S. SHETTY, JEFFREY T. BUDD, DIANA BARB, SRILAXMI KALAVALAPALLI, KENNETH CUSI
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1366-P
https://doi.org/10.2337/db23-1366-P
Published: 20 June 2023
View articletitled, 1366-P: Nonalcoholic Fatty Liver Disease in Young-Onset Type 2 Diabetes Mellitus—A New Epidemic?
Meeting Abstracts

1284-P: Prediabetes with Obesity Is a Major Risk Factor for NAFLD and Liver Fibrosis

EDDISON GODINEZ LEIVA, ROMINA LOMONACO, SULAV SHRESTHA, STEPHEN A. MARANGI, XIAOFEI CHI, SRILAXMI KALAVALAPALLI, SHWETHA S. SHETTY, ANDREA ORTIZ ROCHA, ENRIQUE VALDEZ SAENZ, MARIA A. GONZALEZ, LYDIA MANSOUR, MARIANNA M. CALVET, DIANA BARB, APRIL MATHEWS, ANU SHARMA, KENNETH CUSI
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1284-P
https://doi.org/10.2337/db23-1284-P
Published: 20 June 2023
View articletitled, 1284-P: Prediabetes with Obesity Is a Major Risk Factor for NAFLD and Liver Fibrosis
Meeting Abstracts

1338-P: Characteristics of Patients with Type 2 Diabetes without Nonalcoholic Fatty Liver Disease (NAFLD)

ENRIQUE VALDEZ SAENZ, EDDISON GODINEZ LEIVA, ROMINA LOMONACO, STEPHEN A. MARANGI, SRILAXMI KALAVALAPALLI, MARIA A. GONZALEZ, XIAOFEI CHI, ANDREA ORTIZ ROCHA, YASMINE MOHSENI, DIANA BARB, MATTHEW J. GURKA, ANU SHARMA, KENNETH CUSI
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1338-P
https://doi.org/10.2337/db23-1338-P
Published: 20 June 2023
View articletitled, 1338-P: Characteristics of Patients with Type 2 Diabetes without Nonalcoholic Fatty Liver Disease (NAFLD)
Meeting Abstracts

1396-P: Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis among Subjects without Type 2 Diabetes (T2D)

PEGAH GOLABI, JAMES M. PAIK, AMEETA KUMAR, NAGASHREE GUNDURAO, KENNETH CUSI, ZOBAIR YOUNOSSI
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1396-P
https://doi.org/10.2337/db23-1396-P
Published: 20 June 2023
View articletitled, 1396-P: Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis among Subjects without Type 2 Diabetes (T2D)
Meeting Abstracts

1395-P: The Impact of Type 2 Diabetes on the Outcomes of Solid Organ Transplants in the U.S.

MARIA STEPANOVA, AMEETA KUMAR, PAMELA BRANDT, NAGASHREE GUNDURAO, KENNETH CUSI, ZOBAIR YOUNOSSI
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1395-P
https://doi.org/10.2337/db23-1395-P
Published: 20 June 2023
View articletitled, 1395-P: The Impact of Type 2 Diabetes on the Outcomes of Solid Organ Transplants in the U.S.
Meeting Abstracts

1361-P: Patients with Severe Nonalcoholic Steatohepatitis (NASH) Have Profound Insulin Resistance and Lipotoxicity

STEPHEN A. MARANGI, SRILAXMI KALAVALAPALLI, EDDISON GODINEZ LEIVA, HELENA B. THOMAIDES-BREARS, CHARLIE DIAMOND, YASMINE MOHSENI, MARIA A. GONZALEZ, ANDREA ORTIZ ROCHA, ENRIQUE VALDEZ SAENZ, SULAV SHRESTHA, LYDIA MANSOUR, SHWETHA S. SHETTY, MARIANNA M. CALVET, ROMINA LOMONACO, DIANA BARB, KENNETH CUSI
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1361-P
https://doi.org/10.2337/db23-1361-P
Published: 20 June 2023
View articletitled, 1361-P: Patients with Severe Nonalcoholic Steatohepatitis (NASH) Have Profound Insulin Resistance and Lipotoxicity
Meeting Abstracts

1339-P: Hepatic Steatosis and Fibrosis Are Common in Obese Patients with Type 2 Diabetes Mellitus (T2DM)

ENRIQUE VALDEZ SAENZ, EDDISON GODINEZ LEIVA, ROMINA LOMONACO, SRILAXMI KALAVALAPALLI, STEPHEN A. MARANGI, MARIA A. GONZALEZ, ANDREA ORTIZ ROCHA, XIAOFEI CHI, MATTHEW J. GURKA, DIANA BARB, ANU SHARMA, KENNETH CUSI
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1339-P
https://doi.org/10.2337/db23-1339-P
Published: 20 June 2023
View articletitled, 1339-P: Hepatic Steatosis and Fibrosis Are Common in Obese Patients with Type 2 Diabetes Mellitus (T2DM)
Meeting Abstracts

1349-P: People with Type 2 Diabetes Have a High Prevalence of Nonalcoholic Steatohepatitis with Significant Fibrosis When Screened by NIS4 or Elastography

SRILAXMI KALAVALAPALLI, EDDISON GODINEZ LEIVA, ROMINA LOMONACO, STEPHEN A. MARANGI, ENRIQUE VALDEZ SAENZ, ANDREA ORTIZ ROCHA, JEFFREY T. BUDD, YASMINE MOHSENI, KELLY Y. CHUN, TONI R. PREZANT, MARGERY A. CONNELLY, DIANA BARB, KENNETH CUSI
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1349-P
https://doi.org/10.2337/db23-1349-P
Published: 20 June 2023
View articletitled, 1349-P: People with Type 2 Diabetes Have a High Prevalence of Nonalcoholic Steatohepatitis with Significant Fibrosis When Screened by NIS4 or Elastography
Meeting Abstracts

759-P: Changes in Liver Fat in Patients with Type 2 Diabetes by Presence of Genetic Hepatic Steatosis in the SURPASS-3 MRI Substudy

KENNETH CUSI, AMALIA GASTALDELLI, LAURA FERNANDEZ LANDO, MINZHI LIU, AMELIA TORCELLO-GOMEZ, ÁNGEL RODRÍGUEZ
Journal: Diabetes
Diabetes 2023;72(Supplement_1):759-P
https://doi.org/10.2337/db23-759-P
Published: 20 June 2023
View articletitled, 759-P: Changes in Liver Fat in Patients with Type 2 Diabetes by Presence of Genetic Hepatic Steatosis in the SURPASS-3 MRI Substudy
Meeting Abstracts

758-P: Changes in Liver and Abdominal Fat in Tirzepatide-Treated Patients Achieving Normoglycemia in the SURPASS-3 MRI Substudy

ÁNGEL RODRÍGUEZ, KENNETH CUSI, AMALIA GASTALDELLI, CLAUDIA NICOLAY, AMELIA TORCELLO-GOMEZ, LAURA FERNANDEZ LANDO
Journal: Diabetes
Diabetes 2023;72(Supplement_1):758-P
https://doi.org/10.2337/db23-758-P
Published: 20 June 2023
View articletitled, 758-P: Changes in Liver and Abdominal Fat in Tirzepatide-Treated Patients Achieving Normoglycemia in the SURPASS-3 MRI Substudy
Meeting Abstracts

1342-P: Are Plasma Aminotransferases of Value in Screening Patients with T2DM for NAFLD or Fibrosis?

ANDREA ORTIZ ROCHA, EDDISON GODINEZ LEIVA, SRILAXMI KALAVALAPALLI, ROMINA LOMONACO, SHWETHA S. SHETTY, STEPHEN A. MARANGI, ENRIQUE VALDEZ SAENZ, SULAV SHRESTHA, MARIA A. GONZALEZ, XIAOFEI CHI, MATTHEW J. GURKA, DIANA BARB, KENNETH CUSI
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1342-P
https://doi.org/10.2337/db23-1342-P
Published: 20 June 2023
View articletitled, 1342-P: Are Plasma Aminotransferases of Value in Screening Patients with T2DM for NAFLD or Fibrosis?
Meeting Abstracts

1545-P: Characterization of Metabolic Defects in Pancreatic Cancer–Related Diabetes and Type 2 Diabetes in the DETECT Study

FREDERICO G.S. TOLEDO, YISHENG LI, FUCHENCHU WANG, DHIRAJ YADAV, MELENA BELLIN, KENNETH CUSI, WILLIAM E. FISHER, YOGISH C. KUDVA, WALTER PARK, ROBERT V. CONSIDINE, SURESH T. CHARI, SARAH C. GRAHAM, DANA K. ANDERSEN, JO ANN RINAUDO, JOSE SERRANO, MARK O. GOODARZI, PHIL HART
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1545-P
https://doi.org/10.2337/db23-1545-P
Published: 20 June 2023
View articletitled, 1545-P: Characterization of Metabolic Defects in Pancreatic Cancer–Related Diabetes and Type 2 Diabetes in the DETECT Study
Meeting Abstracts

1346-P: Obesity and Type 2 Diabetes in Patients with NAFLD Are Independently Associated with the Risk of Liver Fibrosis, Insulin Resistance, and Atherogenic Dyslipidemia

APRIL MATHEWS, SRILAXMI KALAVALAPALLI, EDDISON GODINEZ, ROMINA LOMONACO, RACHEL E. DILLARD, MARIA A. GONZALEZ, STEPHEN A. MARANGI, SHWETHA S. SHETTY, SULAV SHRESTHA, LYDIA MANSOUR, MARGERY A. CONNELLY, KELLY Y. CHUN, DIANA BARB, KENNETH CUSI
Journal: Diabetes
Diabetes 2022;71(Supplement_1):1346-P
https://doi.org/10.2337/db22-1346-P
Published: 01 June 2022
View articletitled, 1346-P: Obesity and Type 2 Diabetes in Patients with NAFLD Are Independently Associated with the Risk of Liver Fibrosis, Insulin Resistance, and Atherogenic Dyslipidemia
Meeting Abstracts

210-OR: Presence of Type 2 Diabetes (T2D) Affects HDL Particle Proteomic Composition Independently of Obesity or Fatty Liver

FERNANDO BRIL, RYAN PEARCE, TIMOTHY S. COLLIER, SRILAXMI KALAVALAPALLI, MICHAEL J. MCPHAUL, KENNETH CUSI
Journal: Diabetes
Diabetes 2022;71(Supplement_1):210-OR
https://doi.org/10.2337/db22-210-OR
Published: 01 June 2022
View articletitled, 210-OR: Presence of Type 2 Diabetes (T2D) Affects HDL Particle Proteomic Composition Independently of Obesity or Fatty Liver
Meeting Abstracts

1349-P: Bariatric Surgery Causes an Early Improvement in the Lipidomic Profile and a Decrease in Plasma Ceramides and Diacylglycerols in Patients with Type 2 Diabetes and NAFLD

SRILAXMI KALAVALAPALLI, DIANA BARB, RACHEL E. DILLARD, EDDISON GODINEZ, JEFFREY FRIEDMAN, NADA FANOUS, CURTIS O. WARREN, FERNANDO BRIL, ROMINA LOMONACO, ALI ZARRINPAR, KENNETH CUSI
Journal: Diabetes
Diabetes 2022;71(Supplement_1):1349-P
https://doi.org/10.2337/db22-1349-P
Published: 01 June 2022
View articletitled, 1349-P: Bariatric Surgery Causes an Early Improvement in the Lipidomic Profile and a Decrease in Plasma Ceramides and Diacylglycerols in Patients with Type 2 Diabetes and NAFLD
Meeting Abstracts

869-P: Reductions in Traditional Risk Factors Explain Most of the Cardiovascular Benefit of SGLT2 Inhibitors and GLP-1 Receptor Agonists: An Analysis Using the BRAVO Risk Engine

SHU NIU, DAWEI GUAN, NAYKKY SINGH OSPINA, KENNETH CUSI, VIVIAN FONSECA, LIZHENG SHI, HUI SHAO
Journal: Diabetes
Diabetes 2022;71(Supplement_1):869-P
https://doi.org/10.2337/db22-869-P
Published: 01 June 2022
View articletitled, 869-P: Reductions in Traditional Risk Factors Explain Most of the Cardiovascular Benefit of SGLT2 Inhibitors and GLP-1 Receptor Agonists: An Analysis Using the BRAVO Risk Engine